bio-techne corp. - TECH

TECH

Close Chg Chg %
72.25 -0.17 -0.24%

Closed Market

72.08

-0.17 (0.24%)

Volume: 3.82M

Last Updated:

Sep 10, 2026, 4:00 PM EDT

Company Overview: bio-techne corp. - TECH

TECH Key Data

Open

$72.26

Day Range

72.08 - 72.33

52 Week Range

43.20 - 72.62

Market Cap

$11.34B

Shares Outstanding

156.82M

Public Float

155.97M

Beta

1.28

Rev. Per Employee

N/A

P/E Ratio

62.43

EPS

$1.17

Yield

44.29%

Dividend

$0.08

EX-DIVIDEND DATE

Aug 24, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

2.38M

 

TECH Performance

1 Week
 
-0.48%
 
1 Month
 
-0.44%
 
3 Months
 
33.48%
 
1 Year
 
40.62%
 
5 Years
 
-44.21%
 

TECH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔

About bio-techne corp. - TECH

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. The firm's products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

TECH At a Glance

Bio-Techne Corp.
614 McKinley Place NE
Minneapolis, Minnesota 55413-2610
Phone 1-612-379-8854 Revenue 1.22B
Industry Biotechnology Net Income 181.84M
Sector Health Technology Employees 3,000
Fiscal Year-end 06 / 2027
View SEC Filings

TECH Valuation

P/E Current 62.433
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 61.00
Price to Sales Ratio 9.129
Price to Book Ratio 5.231
Price to Cash Flow Ratio 37.98
Enterprise Value to EBITDA 29.819
Enterprise Value to Sales 9.15
Total Debt to Enterprise Value 0.026

TECH Efficiency

Revenue/Employee 405,013.00
Income Per Employee 60,613.333
Receivables Turnover 5.51
Total Asset Turnover 0.464

TECH Liquidity

Current Ratio 4.547
Quick Ratio 3.352
Cash Ratio 1.617

TECH Profitability

Gross Margin 64.107
Operating Margin 22.67
Pretax Margin 19.808
Net Margin 14.966
Return on Assets 6.945
Return on Equity 9.031
Return on Total Capital 7.585
Return on Invested Capital 7.687

TECH Capital Structure

Total Debt to Total Equity 13.712
Total Debt to Total Capital 12.059
Total Debt to Total Assets 10.791
Long-Term Debt to Equity 13.004
Long-Term Debt to Total Capital 11.436
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-techne Corp. - TECH

Collapse All in section
All values USD millions. 2023 2024 2025 2026 5-year trend
Sales/Revenue
1.14B 1.16B 1.22B 1.22B
Sales Growth
+2.81% +1.97% +5.23% -0.38%
Cost of Goods Sold (COGS) incl D&A
366.89M 385.99M 440.59M 436.11M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
107.24M 111.71M 109.90M 97.36M
Depreciation
29.75M 31.86M 34.58M 35.57M
Amortization of Intangibles
77.49M 79.85M 75.32M 61.79M
COGS Growth
-4.11% +5.21% +14.15% -1.02%
Gross Income
769.82M 773.07M 779.04M 778.93M
Gross Income Growth
+6.48% +0.42% +0.77% -0.01%
Gross Profit Margin
+67.72% +66.70% +63.88% +64.11%
2023 2024 2025 2026 5-year trend
SG&A Expense
489.11M 498.06M 526.10M 503.47M
Research & Development
92.49M 96.66M 99.50M 94.77M
Other SG&A
396.61M 401.40M 426.61M 408.71M
SGA Growth
+9.78% +1.83% +5.63% -4.30%
Other Operating Expense
- - - -
-
Unusual Expense
(67.56M) 68.04M 150.68M 29.43M
EBIT after Unusual Expense
348.27M 206.97M 102.25M 246.03M
Non Operating Income/Expense
5.05M 7.98M 15.93M 9.71M
Non-Operating Interest Income
3.41M 3.32M 3.89M 4.22M
Equity in Earnings of Affiliates
- (6.84M) 938.00K 887.00K
Interest Expense
14.67M 29.26M 19.72M 15.06M
Interest Expense Growth
-16.95% +99.50% -32.62% -23.62%
Gross Interest Expense
14.67M 29.26M 19.72M 15.06M
Interest Capitalized
- - - -
-
Pretax Income
338.66M 185.69M 98.46M 240.68M
Pretax Income Growth
+12.37% -45.17% -46.97% +144.44%
Pretax Margin
+29.79% +16.02% +8.07% +19.81%
Income Tax
53.22M 17.58M 25.06M 58.82M
Income Tax - Current - Domestic
72.56M 45.08M 64.99M 22.29M
Income Tax - Current - Foreign
10.45M 12.66M 11.22M 12.85M
Income Tax - Deferred - Domestic
(31.24M) (32.86M) (50.74M) 23.48M
Income Tax - Deferred - Foreign
1.44M (7.30M) (416.00K) 200.00K
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- (6.84M) 938.00K 887.00K
Other After Tax Income (Expense)
(70.00K) (33.00K) (37.00K) (22.00K)
Consolidated Net Income
285.37M 168.07M 73.36M 181.84M
Minority Interest Expense
- - - 179.00K
-
Net Income
285.19M 168.07M 73.36M 181.84M
Net Income Growth
+4.88% -41.07% -56.35% +147.86%
Net Margin Growth
+25.09% +14.50% +6.02% +14.97%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
285.19M 168.07M 73.36M 181.84M
Preferred Dividends
- - - -
-
Net Income Available to Common
285.19M 168.07M 73.36M 181.84M
EPS (Basic)
1.8144 1.0657 0.4657 1.1659
EPS (Basic) Growth
+4.67% -41.26% -56.30% +150.35%
Basic Shares Outstanding
157.18M 157.71M 157.52M 155.96M
EPS (Diluted)
1.762 1.0454 0.4593 1.1582
EPS (Diluted) Growth
+6.34% -40.67% -56.06% +152.17%
Diluted Shares Outstanding
161.85M 160.77M 159.72M 157.01M
EBITDA
387.95M 386.72M 362.84M 372.81M
EBITDA Growth
+2.73% -0.32% -6.18% +2.75%
EBITDA Margin
+34.13% +33.37% +29.75% +30.68%

Snapshot

Average Recommendation HOLD Average Target Price 71.091
Number of Ratings 16 Current Quarters Estimate 0.44
FY Report Date 09 / 2026 Current Year's Estimate 2.055
Last Quarter’s Earnings 0.52 Median PE on CY Estimate N/A
Year Ago Earnings 1.93 Next Fiscal Year Estimate 2.34
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 13 8
Mean Estimate 0.44 0.48 2.06 2.34
High Estimates 0.47 0.51 2.15 2.60
Low Estimate 0.42 0.46 1.95 2.21
Coefficient of Variance 4.35 4.51 2.90 5.80

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 2 5
OVERWEIGHT 0 0 0
HOLD 15 15 13
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Overweight

Insider Actions for Bio-techne Corp. - TECH

Date Name Shares Transaction Value
Feb 20, 2026 Amy E. Herr Director 200 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $59.1 per share 11,820.00

Bio-Techne Corp. in the News

Foxconn, Wisconsin reach new deal on scaled back facility

Foxconn Technology Group, the world's largest electronics manufacturer, has reached a new deal with reduced tax breaks for its scaled back manufacturing facility in southeast Wisconsin, Gov. Tony Evers and the the company announced on Monday.